Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike other cancer treatment companies, such as Dendreon (NASDAQ: DNDN), Oncothyreon (NASDAQ: ONTY) , IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer recurrence.

The company recently announced an update to its ICT-107 clinical trial for glioblastoma multiforme (GBM).  Patients are enrolling in 23 major clinical centers including the Arizona Cancer Center, Cleveland Clinic, Moffitt Cancer Center, University of Pennsylvania, Penn State, Baylor, UC San Diego, Northwestern, Rush University Medical Center, NYU Clinical Cancer Center, and others. The clinical centers currently recruiting for this clinical trial and enrollment criteria are listed at: http://clinicaltrials.gov/ct2/show/study/NCT01280552?term=ICt-107&rank=1.

ICT-107 is the Company’s lead dendritic cell based cancer vaccine candidate targeting multiple tumor antigens on cancer stem cells for the treatment of GBM. The trial is expected to enroll approximately 160-200 patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There are 115 patients enrolled in the study to date, ahead of the Company’s schedule. Enrollment for the trial is expected to be completed by the second quarter of 2012 and an interim analysis is expected when 50% of events (32 deaths) have been observed.

The Phase I clinical study of ICT-107 in GBM, 16 newly diagnosed patients who received the vaccine in addition to standard of care of surgery, radiation and chemotherapy, demonstrated two year overall survival of 80 percent and a three year survival of 55 percent. The most impressive part of this trial is six out of the 16 (37.6%) patients who received ICT-107 continue to show no tumor recurrence at the last analysis, with 3 of these patients (18.8%) remaining disease-free for more than 4 years.

If the Phase II data demonstrates similar results as phase I study, ICT-107 could change the treatment paradigm for the most aggressive brain cancers (GBM) which have eluded drug developers for the last 30 years.